Abivax's ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for success - Pharma Technology Focus | Issue 98 | September 2020
![Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing | Scientific Reports Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-018-37813-y/MediaObjects/41598_2018_37813_Fig1_HTML.png)
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing | Scientific Reports
![Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial - Gastroenterology Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2dbf1880-7d09-4e0a-ad69-e6febbe82248/fx1ad_lrg.jpg)
Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial - Gastroenterology
![Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis | Retrovirology | Full Text Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis | Retrovirology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12977-015-0159-3/MediaObjects/12977_2015_159_Fig4_HTML.gif)
Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis | Retrovirology | Full Text
![Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing. - Abstract - Europe PMC Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6349857/bin/41598_2018_37813_Fig4_HTML.jpg)
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing. - Abstract - Europe PMC
![Targeting the Long Non-Coding RNA LINC00599-205 splicing by novel candidate drug ABX464 to produce the anti-inflammatory microRNA miR-124 | bioRxiv Targeting the Long Non-Coding RNA LINC00599-205 splicing by novel candidate drug ABX464 to produce the anti-inflammatory microRNA miR-124 | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2020/05/30/2019.12.11.871335/F8.large.jpg)
Targeting the Long Non-Coding RNA LINC00599-205 splicing by novel candidate drug ABX464 to produce the anti-inflammatory microRNA miR-124 | bioRxiv
![Abivax's ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for success - Pharma Technology Focus | Issue 98 | September 2020 Abivax's ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for success - Pharma Technology Focus | Issue 98 | September 2020](https://pharma.nridigital.com/pharma/pharma_sept20/abivax_abx464_covid-19_trial_design/1105616/__screenshot.jpg)
Abivax's ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for success - Pharma Technology Focus | Issue 98 | September 2020
![Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases - ScienceDirect Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1359644620305377-gr1.jpg)
Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases - ScienceDirect
![Targeting the Long Non-Coding RNA LINC00599-205 splicing by novel candidate drug ABX464 to produce the anti-inflammatory microRNA miR-124 | bioRxiv Targeting the Long Non-Coding RNA LINC00599-205 splicing by novel candidate drug ABX464 to produce the anti-inflammatory microRNA miR-124 | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2020/05/30/2019.12.11.871335/F7.large.jpg)
Targeting the Long Non-Coding RNA LINC00599-205 splicing by novel candidate drug ABX464 to produce the anti-inflammatory microRNA miR-124 | bioRxiv
![Targeting the Long Non-Coding RNA LINC00599-205 Splicing by Novel Candidate Drug ABX464 To Produce the Anti-Inflammatory MicroRNA MiR-124 Targeting the Long Non-Coding RNA LINC00599-205 Splicing by Novel Candidate Drug ABX464 To Produce the Anti-Inflammatory MicroRNA MiR-124](https://biomedgrid.com/img/volume7/american-journal-of-biomedical-science-&-research.ID.001140.G001.png)
Targeting the Long Non-Coding RNA LINC00599-205 Splicing by Novel Candidate Drug ABX464 To Produce the Anti-Inflammatory MicroRNA MiR-124
![Frontiers | Microglial Cells: The Main HIV-1 Reservoir in the Brain | Cellular and Infection Microbiology Frontiers | Microglial Cells: The Main HIV-1 Reservoir in the Brain | Cellular and Infection Microbiology](https://www.frontiersin.org/files/Articles/484064/fcimb-09-00362-HTML/image_m/fcimb-09-00362-g001.jpg)
Frontiers | Microglial Cells: The Main HIV-1 Reservoir in the Brain | Cellular and Infection Microbiology
![ABIVAX's ABX464 Reduces HIV Reservoir in Blood in Second Phase 2a Clinical Trial | World Pharma Today ABIVAX's ABX464 Reduces HIV Reservoir in Blood in Second Phase 2a Clinical Trial | World Pharma Today](https://www.worldpharmatoday.com/wp-content/uploads/2017/09/images_article_Clinical_Trial_ABIVAX-ABX464-MoA_845x475.jpg)
ABIVAX's ABX464 Reduces HIV Reservoir in Blood in Second Phase 2a Clinical Trial | World Pharma Today
![Targeting the Long Non-Coding RNA LINC00599-205 Splicing by Novel Candidate Drug ABX464 To Produce the Anti-Inflammatory MicroRNA MiR-124 Targeting the Long Non-Coding RNA LINC00599-205 Splicing by Novel Candidate Drug ABX464 To Produce the Anti-Inflammatory MicroRNA MiR-124](https://biomedgrid.com/img/volume7/american-journal-of-biomedical-science-&-research.ID.001140.G004.png)